

Trials Current as of 17<sup>th</sup> November 2017

TUMOUR	TRIAL/AGENT: PHASE 1	KEY POINTS	PI	SC
Any	<a href="#">DpC (CMD): Oral Fe chelating agent</a>	No Biopsy	BM	LD
Any	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>		BM	PM
Any	SHR1316-002 PDL1 IV 4 weekly	Advanced Solid Tumors	BM	DB
SCLC	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	Max 2L prior chemo	BM	PM
NSCLC	<a href="#">Viralytics: Oncolytic virus + pembrolizumab</a>	Prior I-O permitted provided not refractory, biospies preferred	DD	PM
RCC	<a href="#">BMS IDO: IDO inhib + Nivolumab</a>	Paired biopsy	BM	CAH
RCC	<a href="#">Corvus: Adenosine antag +/- PDL1 (atezolizumab)</a>	Paired biopsies, prior I-O permitted	BM	CAH
Bladder TCC	<a href="#">BMS IDO: IDO inhib + nivolumab</a>	Paired biopsies, prior I-O permitted (only 1 slot remaining)	BM	CAH
Bladder TCC	<a href="#">Viralytics: Oncolytic virus + pembrolizumab</a>	Single biopsy, prior I-O permitted provided not refractory, biopsies preferred	DD	PM
Urothelial	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	Max 2 lines prior chemo	BM	PM
Prostate	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	BRCA mutant (germline or somatic) or HRD	BM	PM
Prostate	<a href="#">ES414 antibody mCRPC</a>	Continuous infusion via CADD	AA	LD
Prostate	<a href="#">GSK525762 + abiraterone or enzalutamide mCRPC daily oral</a>	1 biopsy W3	AA	
Melanoma	<a href="#">BMS IDO inhib + nivolumab</a>	Paired biopsies, prior I-O permitted	BM	CAH
HNSCC	<a href="#">BMS IDO: inhib + nivolumab</a>	Paired biopsies, prior I-O permitted (2 slots remain)	BM	CAH
TNBC	<a href="#">Corvus: Adenosine antag+/- PDL1 (atezolizumab)</a>	Paired biopsies, prior I-O permitted, only PDL1 (4 slots remain)	BM	CAH
TNBC	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	BRCA mutant (germline or somatic) or HRD	BM	PM
Ovarian	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	BRCA mutant (germline or somatic) or HRD, platinum sensitive	BM	PM
Ovarian	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	BRCA WT, platinum sensitive	BM	PM
Oesophageal& GOJ	<a href="#">APROC: APR246 plus 5FU/cisplatin</a>	Platinum refractory only, $\leq 2$ lines chemo in met setting	BM	CB
Gastric & GOJ	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	Max 2 lines prior therapy	BM	PM
Pancreas	<a href="#">BGB-A317 / 290:PD1 inh plus PARP inh</a>	Max 1 L prior chemo; BRCA mut if platinum naïve, not if exposed	BM	PM
Colorectal	<a href="#">GSK BET inhibitor</a>	Paired biopsies	BM	LD
GIST	<a href="#">GSK BET inhibitor</a>	Paired biopsies	AA	CAH

Irina A: 22018 Cheryl-Ann H:22788 Penny M: 22429 Chris B: 22393 Louise D: 22921 Chris P: 22415 Laima M: 22924 Lindsay G: 22419 Steph K: 22017 Katie Cao: 22019  
Kim B: 22024

Please note: Katie Cao is replacement coordinator for Lisa Robinson and Steph Kaladis is replacement coordinator for Shelley Firth

Tumour	Trial	TRIAL/AGENT: PHASE 2/3	PI	SC
HNSCC- rec/met	<a href="#">BMS study</a>	Open Label, Randomized, Study of Nivolumab + Ipilimumab Vs Extreme Study Regimen as a 1 <sup>st</sup> line therapy	DD	LM
NSCLC ALK+	<a href="#">ALTA</a>	Open-Label Study of Brigatinib (AP6113) vs Crizotinib	PB	LM
NSCLC	<a href="#">Mirati Lung</a>	PhII MGCD265 in locally advanced or met NSCLC with activating genetic alterations in mesenchymal-epithelial transition factor	PB	LM
NSCLC	<a href="#">BR.31</a>	Double blind placebo adjuvant MEDI4736 in completely resected NSCLC	PB	LM
NSCLC	<a href="#">Fraction lung</a>	A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced NSCLC	BM	LT
NSCLC	<a href="#">OSCILLATE</a>	Ph 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced NSCLC	PB	LT
Mesothelioma	<a href="#">CA209-743</a>	Nivolumab + Ipilimumab vs Pemetrexed with Cisplatin or Carboplatin as 1st line therapy	PB	LM
mRCC	<a href="#">Javelin renal</a>	Open label parallel arm study of Avelumab in combination with Axitinib vs Sunitinib monotherapy in first-line	DP	IA
mRCC	<a href="#">Fraction renal</a>	Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced RCC	DP	IA
mRCC	Medimmune renal	A Ph 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) with Durva vs Nivo Monotherapy in mRCC	AA	LG
Bladder TCC	<a href="#">Adjuvant</a>	Open label study of Atezolizumab vs observation as adjuvant therapy in PDL1 selected, high risk after cystectomy	DP	IA
Bladder TCC	<a href="#">Javelin Bladder</a>	Avelumab + supportive care vs best supportive care alone in patients who did not progress after 1st line therapy	DP	IA
Prostate hi risk	<a href="#">Embark</a>	Enzalutamide + leuprolide, enzalutamide monotherapy + placebo in non-metastatic prostate ca progressing after definitive therapy	DP	CP
Prostate	EH prostate biology	Studies of prostate cancer biology	AA	NN
Prostate	<a href="#">OZM-054</a>	Phase II study of cabazitaxel vs abiraterone or enzalutamide in poor prognosis-m castration-resistant prostate cancer	AA	CP
Prostate	<a href="#">ARCHES</a>	Ph III study in castrate sensitive metastatic prostate ca, enzalutamide vs placebo with LHRH agonist	AA	IA
Prostate	<a href="#">PROfound</a>	Ph III study of Olaparib in MCRPC patient with genetic mutation	AA	IA
Prostate	<a href="#">IMbassador</a>	Ph III rand trial of enzalutamide +/- atezo in patients with MCRPC after failure of androgen synthesis inhibitor after taxane	DP	SK
Prostate	<a href="#">IPATential</a>	Ph III rand trial of abi +/- ipatasertib placebo controlled in asymptomatic or mildly symptomatic MCRPC	DP	LG
Prostate	<a href="#">MDV3800-06 MCRPC</a>	Ph 2 Open-Label 2 arm st Talazoparib in DNA Repair Defects & MCRPC previous Taxane-Based Chemotherapy and Progressed on abi or enza	AA	IA
Prostate	ICE-PAC	A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC)	AA	LG
CRC Stage II	<a href="#">Dynamic</a>	Circulating tumour DNA analysis informing adjuvant chemotherapy	MH	SK
Adj CRC	<a href="#">ASCOLT</a>	Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers	AS	SK
mBRAF mCRC	<a href="#">ARRAY (BEACON)</a>	Open-Label 3-arm study; Encorafenib + Cetuxomab Bimetinib vs Irinotecan/Cetuximab or FOLFIRI/Cetuximab	AS	SK
mCRC	<a href="#">Keynote 177</a>	Pembrolizumab vs chemotherapy in MSI-H or dMMR mCRC	AS	KC
GI NEC	<a href="#">NABNEC</a>	Randomised Ph II: nab-paclitaxel + carboplatin as 1 <sup>st</sup> line treatment	BM	KC
Adj Gastrooes	<a href="#">Checkmate G/O</a>	Nivolumab or placebo in patients with resected lower esophageal or GOJ	AS	SK
Met Gastrooes	<a href="#">INTEGRATE II</a>	Double-blind Placebo-controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer	AS	KC
Met Gastrooes	<a href="#">MSD Gastric</a>	Pembrolizumab versus Paclitaxel after progression on 1 <sup>st</sup> line therapy with platinum and fluoropyrimidine	AS	KC
Met Gastrooes	<a href="#">Javelin gastric</a>	Maintenance therapy with Avelumab vs continuation of 1 <sup>st</sup> line in locally advanced or metastatic	AS	KC
Pancreas	<a href="#">Pancreatic CtDNA</a>	Circulating Tumour DNA as a biomarker	MH	SK
Pancreas	<a href="#">Halo</a>	RDB placebo-contr PEGylated recombinant hyaluronidase (PEGPH20) + nab-Paclitaxel + gemcitabine in hyaluron-high 1 <sup>st</sup> L	MH	KC
Pancreas	<a href="#">PanCo</a>	Ph III study of Oncosil in untreated metastatic or locally pancreatic ca	MH	KB
Endometrial	<a href="#">Millenium Endometrial</a>	Ph2 MLN0128(dual TORC1/2inhibitor), MLN0128+MLN1117(Pi3Ka Inhibitor), weekly paclitaxel or weekly paclitaxel + MLN0128 in advanced, recurrent or persistent EC	GG	KB
Endometrial	<a href="#">PHAEDRA</a>	Ph II trial of Durvalumab in advanced endometrial cancer	GG	KB
Ovarian	DYNAMIC	Circulating Tumour DNA	GG	SK
Breast HER 2+	<a href="#">Penelope B</a>	Palbociclib (CDK) 4/6 inhibitor after neoadjuvant therapy	MW	FB/LR
Breast HER 2+	Tabitha	Treatment of advanced breast ca in the HER-pos australian patient	MH	
Glioblastoma	<a href="#">Vertu</a>	R Ph II veliparib + RT with adjuvant TMZ + veliparib vs RT+TMZ then TMZ in newly diagnosed GBM with unmethylated (MGMT)	RF	IA
Bone Metastases	TANGO bone pain	Placebo controlled, analgesic subcut Tanezumab (PF-04383119) for cancer pain due to bone mets receiving background opioid	MF	SK
Cough	Methadone Cough	Efficacy of low dose methadone as an antitussive for patients with malignancy	MF	
	iPREDICT	INTEGRATION OF GENOMIC SEQUENCING INTO CLINICAL CARE: A DEMONSTRATION EVALUATION.	BM	LT
RARE CANCERS		A PHASE II CLINICAL TRIAL EVALUATING IPI & NIVO FOR THE TREATMENT OF RARE GASTROINTESTINAL, NEURO-ENDOCRINE AND GYNAECOLOGICAL CANCERS	BM	LG